These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 38112106)

  • 1. Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-to-severe COVID-19: Emulation of a randomized target trial.
    Zhou Y; Liu Y; Jiang L; Zhang R; Zhang H; Shi Q; Yang Z; Mao Y; Liu S; Yang Z; Ding J; Zhou Y; Ren B; He L; Zhao X; Li W; Li S; Liu D
    J Med Virol; 2023 Dec; 95(12):e29318. PubMed ID: 38112106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study.
    Deng G; Li D; Sun Y; Jin L; Zhou Q; Xiao C; Wu Q; Sun H; Dian Y; Zeng F; Pan P; Shen M
    J Med Virol; 2023 Apr; 95(4):e28756. PubMed ID: 37185838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study.
    Wang S; Sun J; Zhang X; Li M; Qin B; Liu M; Zhang N; Wang S; Zhou T; Zhang W; Ma C; Deng X; Bai Y; Qu G; Liu L; Shi H; Zhou B; Li K; Yang B; Li S; Wang F; Ma J; Zhang L; Wang Y; An L; Liu W; Chang Q; Zhang R; Yin X; Yang Y; Ao Q; Ma Q; Yan S; Huang H; Song P; Gao L; Lu W; Xu L; Lei L; Wang K; Zhang Q; Song Q; Zhang Z; Fang X; He Y; Li T; Zhu P
    EClinicalMedicine; 2024 Mar; 69():102468. PubMed ID: 38361990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.
    Chen MP; Jiang DX; Rang JX; Zhuo HB; Zhou ZG
    Sci Rep; 2024 Feb; 14(1):3318. PubMed ID: 38337014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Wan EYF; Yan VKC; Mok AHY; Wang B; Xu W; Cheng FWT; Lai FTT; Chui CSL; Li X; Wong CKH; Li PH; Cowling BJ; Hung IFN; Lau CS; Wong ICK; Chan EWY
    Ann Intern Med; 2023 Apr; 176(4):505-514. PubMed ID: 36913693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study.
    Kapar A; Xie S; Guo Z; Nan Y; Du Y; Yin X; Gong T; Gu X; Zhou Y; Lu W; Yang A; Luo Z; Dai J; Wang K; Zhao S; Wang K
    Expert Rev Anti Infect Ther; 2024 Jul; 22(7):569-577. PubMed ID: 38822541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.
    Wei AH; Zeng L; Wang L; Gui L; Zhang WT; Gong XP; Li J; Liu D
    Front Pharmacol; 2023; 14():1274294. PubMed ID: 37900159
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of the antiviral medications azvudine and nirmatrelvir-ritonavir in treating COVID-19 in patients with hematological malignancies.
    Zeng Z; Li F; Zhong M; Zhu L; Chen W; Wang X
    Clinics (Sao Paulo); 2024; 79():100406. PubMed ID: 39059144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study.
    Zhao Q; Zheng B; Han B; Feng P; Xia Z; Jiang H; Ying Y; Zhu J; Fei C; Xiang J; Shen L; Luo Q; Wu Y; Wusiman A; Xin C; Zhang M; Li G; Li X
    Infect Dis Ther; 2023 Aug; 12(8):2087-2102. PubMed ID: 37486556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of azvudine in older adults with mild and moderate COVID-19: a retrospective observational study.
    Zhou Z; Zheng H; Xiao G; Xie X; Rang J; Peng D
    BMC Infect Dis; 2024 Jan; 24(1):47. PubMed ID: 38177982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: A target trial emulation study.
    Wan EYF; Wong ZCT; Yan VKC; Chui CSL; Lai FTT; Li X; Wong ICK; Chan EWY
    Diabetes Obes Metab; 2024 Oct; 26(10):4653-4664. PubMed ID: 39109461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
    Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing.
    Xie H; Wang Y; Xu Y; Wang L; Fan J; Pan S; Shi C; Liu X; Gao X; Guo X; Yu S; Liu J; Zhang D; Yang Y; Zhang H; Wang J; Wu A; Liu X; Liu J; Zhu H; Zhou X; Tian X; Wang M
    Sci Rep; 2024 Oct; 14(1):23974. PubMed ID: 39402091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19.
    Zhang H; Xiaojiao T; Chen J; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
    BMJ Open Respir Res; 2024 Apr; 11(1):. PubMed ID: 38599779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine.
    Yu X; Luo R; Xie G; Ji J; Wang J; Li X; Qian X; Wang X
    Infect Drug Resist; 2024; 17():3967-3978. PubMed ID: 39296775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.
    Chen X; Zhu Y; Shen L; Zhou D; Feng N; Tong Q
    J Intensive Care Med; 2024 Aug; 39(8):742-750. PubMed ID: 38356292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.